X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare AJANTA PHARMA with JUBILANT LIFE SCIENCES - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AJANTA PHARMA vs JUBILANT LIFE SCIENCES - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AJANTA PHARMA JUBILANT LIFE SCIENCES AJANTA PHARMA/
JUBILANT LIFE SCIENCES
 
P/E (TTM) x 21.9 17.0 129.2% View Chart
P/BV x 5.2 4.5 115.4% View Chart
Dividend Yield % 0.0 0.4 -  

Financials

 AJANTA PHARMA   JUBILANT LIFE SCIENCES
EQUITY SHARE DATA
    AJANTA PHARMA
Mar-18
JUBILANT LIFE SCIENCES
Mar-14
AJANTA PHARMA/
JUBILANT LIFE SCIENCES
5-Yr Chart
Click to enlarge
High Rs1,818187 973.2%   
Low Rs1,10665 1,698.9%   
Sales per share (Unadj.) Rs239.5364.3 65.7%  
Earnings per share (Unadj.) Rs52.86.8 771.2%  
Cash flow per share (Unadj.) Rs59.524.5 242.9%  
Dividends per share (Unadj.) Rs03.00 0.0%  
Dividend yield (eoy) %02.4 0.0%  
Book value per share (Unadj.) Rs230.0164.9 139.5%  
Shares outstanding (eoy) m88.77159.28 55.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x6.10.3 1,766.1%   
Avg P/E ratio x27.718.4 150.5%  
P/CF ratio (eoy) x24.65.1 477.9%  
Price / Book Value ratio x6.40.8 832.4%  
Dividend payout %043.8 0.0%   
Avg Mkt Cap Rs m129,78220,061 646.9%   
No. of employees `0006.86.2 109.9%   
Total wages/salary Rs m3,76511,052 34.1%   
Avg. sales/employee Rs Th3,128.49,383.0 33.3%   
Avg. wages/employee Rs Th554.01,786.9 31.0%   
Avg. net profit/employee Rs Th689.7176.3 391.2%   
INCOME DATA
Net Sales Rs m21,25858,034 36.6%  
Other income Rs m242191 126.8%   
Total revenues Rs m21,49958,224 36.9%   
Gross profit Rs m6,5845,786 113.8%  
Depreciation Rs m5962,812 21.2%   
Interest Rs m43,237 0.1%   
Profit before tax Rs m6,226-72 -8,634.5%   
Minority Interest Rs m0-286 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m02,145 0.0%   
Tax Rs m1,539696 221.0%   
Profit after tax Rs m4,6861,090 429.8%  
Gross profit margin %31.010.0 310.6%  
Effective tax rate %24.7-965.9 -2.6%   
Net profit margin %22.01.9 1,173.3%  
BALANCE SHEET DATA
Current assets Rs m12,23629,280 41.8%   
Current liabilities Rs m3,46138,912 8.9%   
Net working cap to sales %41.3-16.6 -248.7%  
Current ratio x3.50.8 469.9%  
Inventory Days Days6084 71.4%  
Debtors Days Days8451 166.7%  
Net fixed assets Rs m11,14055,712 20.0%   
Share capital Rs m177155 114.5%   
"Free" reserves Rs m20,23720,968 96.5%   
Net worth Rs m20,41426,265 77.7%   
Long term debt Rs m1017,169 0.1%   
Total assets Rs m24,48688,606 27.6%  
Interest coverage x1,519.41.0 155,402.6%   
Debt to equity ratio x00.7 0.1%  
Sales to assets ratio x0.90.7 132.6%   
Return on assets %19.24.9 392.2%  
Return on equity %23.04.2 553.0%  
Return on capital %30.511.6 263.7%  
Exports to sales %037.8 0.0%   
Imports to sales %016.5 0.0%   
Exports (fob) Rs mNA21,933 0.0%   
Imports (cif) Rs mNA9,567 0.0%   
Fx inflow Rs m11,66722,004 53.0%   
Fx outflow Rs m1,61611,749 13.8%   
Net fx Rs m10,05210,255 98.0%   
CASH FLOW
From Operations Rs m2,8548,026 35.6%  
From Investments Rs m-2,604-1,744 149.3%  
From Financial Activity Rs m-2-4,447 0.0%  
Net Cashflow Rs m2481,834 13.5%  

Share Holding

Indian Promoters % 73.8 45.6 161.8%  
Foreign collaborators % 0.0 3.5 -  
Indian inst/Mut Fund % 1.6 8.7 17.8%  
FIIs % 7.6 21.2 35.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.0 21.1 80.6%  
Shareholders   20,968 23,815 88.0%  
Pledged promoter(s) holding % 4.4 15.9 27.7%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AJANTA PHARMA With:   WOCKHARDT LTD.  J.B.CHEMICALS  MERCK LTD  BIOCON LTD  FULFORD INDIA  

Compare AJANTA PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 284 Points Up; FMCG & Metal Stocks Top Gainers(Closing)

Indian share markets settled higher today taking cues from their Asian peers. At the closing bell, BSE Sensex ended up by 284 points.

Related Views on News

AJANTA PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 11.6% (Quarterly Result Update)

Aug 1, 2018 | Updated on Aug 1, 2018

For the quarter ended June 2018, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 11.6% YoY). Sales on the other hand came in at Rs 5 bn (up 8.0% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

JUBILANT LIFE SCIENCES Announces Quarterly Results (1QFY19); Net Profit Up 39.4% (Quarterly Result Update)

Jul 31, 2018 | Updated on Jul 31, 2018

For the quarter ended June 2018, JUBILANT LIFE SCIENCES has posted a net profit of Rs 2 bn (up 39.4% YoY). Sales on the other hand came in at Rs 21 bn (up 30.2% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

This is a Must-Have Stock for Your Portfolio(The 5 Minute Wrapup)

Aug 8, 2018

Tanushree just released the permanent wealth blueprint report. This report includes three safe and steady stocks. I like one in particular. Here's why

Trading in These Times: 8% Gains in 3 Days!(Profit Hunter)

Aug 9, 2018

Here are 2 stocks you can buy right now! And there are plenty more opportunities to come...

Banks are Raising FD Rates and That's Good News(Vivek Kaul's Diary)

Aug 7, 2018

Lending to the retail segment remains strong, whereas lending to the service sector has picked up dramatically.

Why HDFC Equity Fund Disappointed Its Investors(Outside View)

Aug 9, 2018

Though popular, HDFC Equity Fund is not among the best performers anymore. Here is the reason behind its underperformance that has left investors disappointed.

HDFC AMC Makes 65% Listing Gains! Should It Attract Mutual Fund Investors?(Outside View)

Aug 8, 2018

PersonalFN explains if investors should invest in schemes of HDFC Mutual Fund looking at the listing gains of HDFC AMC.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AJANTA PHARMA SHARE PRICE


Aug 17, 2018 (Close)

TRACK AJANTA PHARMA

  • Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AJANTA PHARMA 5-YR ANALYSIS

COMPARE AJANTA PHARMA WITH

MARKET STATS